Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 May;24(3):299-304.
doi: 10.1016/j.jsps.2016.04.001. Epub 2016 May 5.

Patients treatment with neuroglioma by teniposide and semustine and its influence on Twist and E-cadherin expression

Yongbo Zhang  1 , Guoyi Liu  1 , Meiling Lang  1 , Jing Zhang  1 , Jia Geng  2
Affiliations

Patients treatment with neuroglioma by teniposide and semustine and its influence on Twist and E-cadherin expression

Yongbo Zhang et al. Saudi Pharm J. 2016 May.

Abstract

This study focuses on curative effects of teniposide combining with semustine on patients with neuroglioma and the influences on the expression of Twist and E-cadherin in tissue. Sixty-eight patients with neuroglioma taking operation in our hospital were divided into two groups randomly. Single radiotherapy was given to 34 patients in group A, and teniposide (VM-26) and semustine (Me-CCUN) were added to radiotherapy for 34 patients in group B. Then, curative effects, survival rate, living quality and adverse reaction rate after operation were compared between two groups. Moreover, the difference in positive expression rate of Twist and E-cadherin before and after treatment between two groups was analyzed by immunohistochemistry.

Results: In group B, the effective rate of treatment was 88.2%, and the disease control rate was 70.6%, higher than 52.9% and 32.4% in group A with statistical significance (P < 0.05). Moreover, the survival rate in three years of group B was 44.1%, and the score of living quality was 67.11 ± 4.32, and also higher than 23.5% and 63.79 ± 4.53 in group A with statistical significance (P < 0.05). However, the difference between two groups in adverse reaction rate has no statistical significance (P > 0.05). In addition, the difference in positive expression rate of Twist and E-cadherin between group A and group B has no statistical significance before treatment (P > 0.05). After treatment, however, the positive rate of Twist in group B is lower than that in group A, while the positive rate of E-cadherin is higher. Both differences have statistical significance (P < 0.05). Chemotherapy of VM-26 combining with Me-CCNU can inhibit Twist expression and improve the expression rate of E-cadherin to help improving the curative effects and living quality and increasing survival rate.

Keywords: E-cadherin; Neuroglioma; Semustine; Teniposide; Twist.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The survival curves of the two groups of patients.
Figure 2
Figure 2
Twist the positive rate of two groups of patients before and after treatment.
Figure 3
Figure 3
(A, C) is group A Twist protein expression before and after treatment, (B, D) is group B Twist protein expression before and after treatment.
Figure 4
Figure 4
E-cadherin the positive rate of two groups of patients before and after treatment.
Figure 5
Figure 5
(A, C) is group A E-cadherin protein expression before and after treatment, (B, D) is group B E-cadherin protein expression before and after treatment.
See this image and copyright information in PMC

References

    1. Ding J., Zhang Z., Pan Y. Expression and significance of twist, E-cadherin, and N-cadherin in gastrointestinal stromal tumors. Digest. Dis. Sci. 2012;57:2318–2324. - PubMed
    1. Fan X.J., Wan X.B., Yang Z.L. Snail promotes lymph node metastasis and Twist enhances tumor deposit formation through epithelial–mesenchymal transition in colorectal cancer. Human Pathol. 2013;44:173–180. - PubMed
    1. He X., Xiang N., Zhang J. Encapsulation of teniposide into albumin nanoparticles with greatly lowered toxicity and enhanced antitumor activity. Int. J. Pharm. 2015;487:250–259. - PubMed
    1. Johnson B.E., Mazor T., Hong C. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science. 2014;343:189–193. - PMC - PubMed
    1. Khan M.A., Chen H., Zhang D. Twist: a molecular target in cancer therapeutics. Tumor Biol. 2013;34:2497–2506. - PubMed

LinkOut - more resources